Sygnature’s integrated drug discovery team offers a dynamic blend of new talent and pharmaceutical industry experience recruited from around the world, with more than 80% of our scientists holding PhDs. Mixed discipline laboratories facilitate clear communication, problem-solving and a rapid response to the changing needs of each clients’ research project.
Our experienced drug hunters possess all the professional skills and know-how required to undertake the most demanding of drug discovery programmes and drive them from target validation, through hit identification, hit-to-lead and lead optimisation to development candidate.
We can develop tailored assay solutions that deliver robust data, even for the most complex projects, spanning a broad range of biophysical, biochemical, cellular and live cell imaging platforms.
Sygnature offers a range of hit finding approaches, including fragment-based screens, medium-throughput screening, high-throughput screening and complementary in silico approaches.
During hit-to-lead projects our high-throughput chemistry capability enables the rapid design and synthesis of novel hit expansion libraries. Subsequent refinement using computational techniques and medicinal chemistry know how, enables our scientific teams to generate high quality leads ready for further optimisation.
We incorporate early ADMET profiling, PK/PD correlations, and human dose prediction. As a consequence, Sygnature has delivered 29 pre-clinical candidates to clients; 14 of which have already progressed to healthy volunteer and patient-based trials.